LENZ Therapeutics, Inc. (LENZ)Healthcare | Biotechnology | Solana Beach, United States | NasdaqGS
5.11 USD
+0.30
(6.237%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.72 -0.39 (-0.388%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:59 a.m. EDT
The investment case for LENZ is currently broken by a catastrophic failure in execution and capital preservation. While the company sits on a fortress-like balance sheet with negligible debt and substantial cash reserves, it has squandered these resources on a decade-long hemorrhage of value, evidenced by a stock price that has collapsed from over $140 to under $5. The recent earnings reports confirm a dire reality: the business is burning through cash at an accelerating rate with no visible path to profitability, forcing analysts to repeatedly reset their growth assumptions downward. The market has correctly identified this as a value trap; the low price is not a bargain but a reflection of a failing operational model. Furthermore, the company recently initiated a massive special dividend, which appears to be a desperate attempt to return remaining capital to shareholders rather than a sign of financial strength, as the underlying operations continue to generate negative free cash flow. With the stock trading below book value yet offering no earnings power or sustainable revenue growth, there is no margin of safety here—only a high risk of further dilution or total capital destruction. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.048554 |
| MSTL | 0.144856 |
| AutoARIMA | 0.148023 |
| AutoETS | 0.148026 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.738 |
| Excess Kurtosis | -0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2024-03-21 |
| Debt to Equity Ratio | 0.26 |
| Revenue per Share | 0.702 |
| Market Cap | 160,557,968 |
| Forward P/E | -1.66 |
| Beta | 1.63 |
| Website | https://www.lenz-tx.com |
As of Aug. 22, 2026, 2:59 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in deep out-of-the-money puts (strikes 2.5 and 7.5) expiring in late 2026 and early 2027. This creates a 'pin risk' zone around the current price, suggesting a high probability of a gap lower at expiration. Conversely, call activity is sparse and concentrated near the money, indicating a lack of aggressive bullish speculation despite the low price.
| Date | Dividend | Yield % |
|---|---|---|
| 2024-03-22 | 7.21 | 44.506171 |
| 2024-03-15 | 7.21 | 30.838324 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8698089 |
| Address1 | 201 Lomas Santa Fe Drive |
| Address2 | Suite 300 |
| All Time High | 238.0 |
| All Time Low | 4.535 |
| Ask | 6.1 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 566,940 |
| Average Daily Volume3 Month | 844,958 |
| Average Volume | 844,958 |
| Average Volume10Days | 566,940 |
| Beta | 1.629 |
| Bid | 3.46 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 6.979 |
| City | Solana Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.11 |
| Current Ratio | 13.553 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.13 |
| Day Low | 4.69 |
| Debt To Equity | 0.26 |
| Display Name | LENZ Therapeutics |
| Dividend Date | 1,710,979,200 |
| Earnings Call Timestamp End | 1,786,480,200 |
| Earnings Call Timestamp Start | 1,786,480,200 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -135,204,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.435 |
| Enterprise To Revenue | -2.742 |
| Enterprise Value | -58,876,048 |
| Eps Current Year | -4.245 |
| Eps Forward | -3.075 |
| Eps Trailing Twelve Months | -4.4 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.2987 |
| Fifty Day Average Change | -0.18869972 |
| Fifty Day Average Change Percent | -0.035612457 |
| Fifty Two Week Change Percent | -86.98089 |
| Fifty Two Week High | 50.4 |
| Fifty Two Week High Change | -45.29 |
| Fifty Two Week High Change Percent | -0.8986111 |
| Fifty Two Week Low | 4.535 |
| Fifty Two Week Low Change | 0.5750003 |
| Fifty Two Week Low Change Percent | 0.12679169 |
| Fifty Two Week Range | 4.535 - 50.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 18,393,155 |
| Forward Eps | -3.075 |
| Forward P E | -1.6617886 |
| Free Cashflow | -71,252,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 152 |
| Fullday Change | 0.3 |
| Fullday Change Percent | 6.23701 |
| Fullday Price | 4.7222 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.91739 |
| Gross Profits | 19,701,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02648 |
| Held Percent Institutions | 1.11751 |
| Implied Shares Outstanding | 31,420,343 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,711,065,600 |
| Last Dividend Value | 7.21 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,711,065,600 |
| Last Split Factor | 1:7 |
| Long Business Summary | LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California. |
| Long Name | LENZ Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 160,557,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_370131860 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -126,002,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 151,131,849 |
| Number Of Analyst Opinions | 7 |
| Open | 4.8 |
| Operating Cashflow | -113,908,000 |
| Operating Margins | -6.22895 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 925 7000 |
| Post Market Change | -0.38780022 |
| Post Market Change Percent | -7.589045 |
| Post Market Price | 4.7222 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 4.81 |
| Price Eps Current Year | -1.2037692 |
| Price Hint | 2 |
| Price To Book | 0.7321966 |
| Price To Sales Trailing12 Months | 7.476506 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.906 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.3 |
| Regular Market Change Percent | 6.23701 |
| Regular Market Day High | 5.13 |
| Regular Market Day Low | 4.69 |
| Regular Market Day Range | 4.69 - 5.13 |
| Regular Market Open | 4.8 |
| Regular Market Previous Close | 4.81 |
| Regular Market Price | 5.11 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 678,662 |
| Return On Assets | -0.37355998 |
| Return On Equity | -0.59208 |
| Revenue Growth | 0.097 |
| Revenue Per Share | 0.702 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 31,420,343 |
| Shares Percent Shares Out | 0.3563 |
| Shares Short | 11,195,137 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,861,316 |
| Short Name | LENZ Therapeutics, Inc. |
| Short Percent Of Float | 0.5861 |
| Short Ratio | 11.44 |
| Source Interval | 15 |
| State | CA |
| Symbol | LENZ |
| Target High Price | 60.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 24.0 |
| Target Median Price | 10.0 |
| Total Cash | 220,003,008 |
| Total Cash Per Share | 7.002 |
| Total Debt | 569,000 |
| Total Revenue | 21,475,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.024025 |
| Two Hundred Day Average Change | -6.914025 |
| Two Hundred Day Average Change Percent | -0.5750175 |
| Type Disp | Equity |
| Volume | 678,662 |
| Website | https://www.lenz-tx.com |
| Zip | 92,075 |